Price T Rowe Associates Inc Replimune Group, Inc. Transaction History
Price T Rowe Associates Inc
- $816 Billion
- Q1 2024
A detailed history of Price T Rowe Associates Inc transactions in Replimune Group, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 6,548,930 shares of REPL stock, worth $53 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
6,548,930
Previous 5,849,251
11.96%
Holding current value
$53 Million
Previous $49.3 Million
8.51%
% of portfolio
0.01%
Previous 0.01%
Shares
14 transactions
Others Institutions Holding REPL
# of Institutions
154Shares Held
66.1MCall Options Held
79.4KPut Options Held
102K-
Baker Bros. Advisors LP New York, NY9.55MShares$77.2 Million0.99% of portfolio
-
State Street Corp Boston, MA6.49MShares$52.5 Million0.0% of portfolio
-
Fcpm Iii Services B.V. Naarden, P74.87MShares$39.4 Million5.62% of portfolio
-
Black Rock Inc. New York, NY4.61MShares$37.3 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA3.73MShares$30.2 Million1.2% of portfolio
About Replimune Group, Inc.
- Ticker REPL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,306,700
- Market Cap $399M
- Description
- Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...